Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norbaeocystin is a naturally occurring tryptamine alkaloid found as a minor compound in psilocybin-containing mushrooms, serving as a phosphorylated derivative of 4-hydroxytryptamine (4-HT) and an N-demethylated analog of baeocystin and psilocybin. It acts as a prodrug that is dephosphorylated to 4-HT, a potent serotonin 5-HT2A receptor agonist with central penetrance and interactions at other serotonin receptors, though it exhibits β-arrestin2-preferring biased agonism that putatively renders it non-hallucinogenic, as evidenced by lack of head-twitch response in animal models unlike psilocybin. Recent biosynthetic platforms using engineered E. coli enable gram-scale production for preclinical studies exploring potential therapeutic efficacy, such as antidepressant effects in stress-induced depression models.[1][3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norbaeocystin.